ArticleMolecular psychiatry2017
Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [
Article in Molecular psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences.Biological psychiatry · 2021Pooled it
- Neuroinflammation in schizophrenia: meta-analysis ofPsychological medicine · 2019Pooled it
- Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data.Biological psychiatry · 2018Pooled it
- Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [Molecular imaging and biology · 2019Trial
- A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Trial
- PET Imaging Unveils Neuroinflammatory Mechanisms in Psychiatric Disorders: From Microglial Activation to Therapeutic Innovation.Molecular neurobiology · 2025Review
- TSPO activation ameliorates maternal immune activation induced PV interneuron deficits via BDNF/TrkB signaling.Psychopharmacology · 2025Article
- PET imaging of neuroinflammation: any credible alternatives to TSPO yet?Molecular psychiatry · 2025Review
- Microglia-neuron interactions in schizophrenia.Frontiers in cellular neuroscience · 2024Review
- Review
- Positron Emission Tomography of Neuroimmune Responses in Humans: Insights and Intricacies.Seminars in nuclear medicine · 2023Review
- New insight in the cross-talk between microglia and schizophrenia: From the perspective of neurodevelopment.Frontiers in psychiatry · 2023Review
- Microglia sequelae: brain signature of innate immunity in schizophrenia.Translational psychiatry · 2022Review
- In vivo imaging translocator protein (TSPO) in autism spectrum disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Plasma Soluble P-selectin, Interleukin-6 and S100B Protein in Patients with Schizophrenia: a Pilot Study.The Psychiatric quarterly · 2022Article
- Distinct Phenotypes of Inflammation Associated Macrophages and Microglia in the Prefrontal Cortex Schizophrenia Compared to Controls.Frontiers in neuroscience · 2022Article
- Reduced microglia activity in patients with long-term immunosuppressive therapy after liver transplantation.European journal of nuclear medicine and molecular imaging · 2021Article
- Applicability, potential and limitations of TSPO PET imaging as a clinical immunopsychiatry biomarker.European journal of nuclear medicine and molecular imaging · 2021Review
- NRM 2021 Abstract Booklet.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several lines of evidence are indicative of a role for immune activation in the pathophysiology of schizophrenia. Nevertheless, studies using positron emission tomography (PET) and radioligands for the translocator protein (TSPO), a marker for glial activation, have yielded inconsistent results. Whereas early studies using a radioligand with low signal-to-noise in small samples showed increases in patients, more recent studies with improved methodology have shown no differences or trend-level decreases. Importantly, all patients investigated thus far have been on antipsychotic medication, and as these compounds may dampen immune cell activity, this factor limits the conclusions that can be drawn. Here, we examined 16 drug-naive, first-episode psychosis patients and 16 healthy controls using PET and the TSPO radioligand [
Indexed as
Identifiers
28194003What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.